[Translation] A randomized, double-blind, single-dose, parallel comparison of the pharmacokinetic characteristics of humanized anti-VEGF monoclonal antibody injection and bevacizumab injection (Avastin) in healthy Chinese male volunteers

主要研究目的：比较试验药物人源化抗VEGF单抗注射液（规格：100mg/4mL，北京赛升药业股份有限公司生产）和对照药物贝伐珠单抗注射液[Avastin，安维汀，规格： 100mg/4mL，Roche Diagnostics GmbH生产（欧洲来源），北京赛升药业股份有限公司提供]在中国健康男性志愿者以 1mg/kg单次静脉滴注给药的药代动力学（PK）相似性。次要研究目的：评价人源化抗VEGF单抗注射液和贝伐珠单抗注射液（Avastin，安维汀）在中国健康男性志愿者单次静脉滴注给药的安全性、耐受性和免疫原性。

[Translation]

The primary study objective was to compare the pharmacokinetic (PK) similarity of the experimental drug humanized anti-VEGF monoclonal antibody injection (specification: 100 mg/4 mL, produced by Beijing Saisheng Pharmaceutical Co., Ltd.) and the control drug bevacizumab injection [Avastin, specification: 100 mg/4 mL, produced by Roche Diagnostics GmbH (European source), provided by Beijing Saisheng Pharmaceutical Co., Ltd.] in healthy Chinese male volunteers after a single intravenous drip of 1 mg/kg. The secondary study objective was to evaluate the safety, tolerability and immunogenicity of humanized anti-VEGF monoclonal antibody injection and bevacizumab injection (Avastin) in healthy Chinese male volunteers after a single intravenous drip.

Start Date22 Mar 2023

Sponsor / Collaborator

Beijing Lüzhu Biotechnology Co., Ltd.

CTR20171588

/ RecruitingPhase 1

随机双盲平行比较试验药和安维汀在健康男性受试者中单次给药药代动力学、安全性及免疫原性的Ⅰ期临床研究

[Translation] A randomized, double-blind, parallel comparison phase I clinical study on the pharmacokinetics, safety, and immunogenicity of a single-dose trial drug and Avastin in healthy male subjects

评价单次给药后人源化抗VEGF单抗注射液和安维汀主要药代动力学参数（AUC0-t）的相似性。评价单次给药后人源化抗VEGF单抗注射液和安维汀其他PK参数（AUC0-∞、Cmax 、MRT、T1/2、Vd、CL）、安全性和免疫原性的相似性。

[Translation]

To evaluate the similarity of the main pharmacokinetic parameters (AUC0-t) of humanized anti-VEGF monoclonal antibody injection and Avastin after a single dose. To evaluate the similarity of other PK parameters (AUC0-∞, Cmax, MRT, T1/2, Vd, CL), safety and immunogenicity of humanized anti-VEGF monoclonal antibody injection and Avastin after a single dose.

Start Date14 Dec 2017

Sponsor / Collaborator

Beijing Lüzhu Biotechnology Co., Ltd.

CTR20242804

/ Not yet recruitingPhase 3

比较人源化抗VEGF单抗或贝伐珠单抗分别联合奥沙利铂和氟尿嘧啶类一线治疗转移性结直肠癌的有效性、安全性及免疫原性的随机、双盲、平行对照的Ⅲ期临床试验

[Translation] A randomized, double-blind, parallel-controlled phase III clinical trial comparing the efficacy, safety, and immunogenicity of humanized anti-VEGF monoclonal antibody or bevacizumab combined with oxaliplatin and fluorouracil as first-line treatment for metastatic colorectal cancer

[Translation]

A randomized, double-blind, parallel-controlled phase III clinical trial comparing the efficacy, safety, and immunogenicity of humanized anti-VEGF monoclonal antibody or bevacizumab combined with oxaliplatin and fluorouracil as first-line treatment for metastatic colorectal cancer

Start Date-

Sponsor / Collaborator

Beijing Lüzhu Biotechnology Co., Ltd.

100 Clinical Results associated with Bevacizumab(Beijing Science Sun)

100 Translational Medicine associated with Bevacizumab(Beijing Science Sun)

100 Patents (Medical) associated with Bevacizumab(Beijing Science Sun)

100 Deals associated with Bevacizumab(Beijing Science Sun)

External Link

KEGG	Wiki	ATC	Drug Bank
D06409	-	-	DB00112

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Colorectal Carcinoma	Phase 3	China	Beijing Lüzhu Biotechnology Co., Ltd.	31 Jul 2024
Non-Small Cell Lung Cancer	Phase 1	China	Beijing Lüzhu Biotechnology Co., Ltd.	14 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis